CTOs on the Move

Aldeyra Therapeutics, Inc

www.aldeyra.com

 
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.aldeyra.com
  • 15 New England Executive Park
    Burlington, MA USA 01803
  • Phone: 781.270.0630

Executives

Name Title Contact Details

Funding

Aldeyra Therapeutics, Inc raised $60M on 03/26/2019
Aldeyra Therapeutics, Inc raised $74.7M on 01/20/2021
Aldeyra Therapeutics, Inc raised $125M on 04/28/2021

Similar Companies

CellCarta

CellCarta provides integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as digital pathology & AI.

Atreca

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients` immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today`s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health.

Botanix Pharmaceuticals

Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.

Ferre Institute

Ferre Institute is a Binghamton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

healthchemdiagnostics

healthchemdiagnostics is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.